Aktuelle gentherapeutische Behandlungsansätze bei Hämoglobinopathien

ZUSAMMENFASSUNG

Die Erfolge des Gentransfers in hämatopoetische Stammzellen bei Säuglingen mit schweren Immundefekten haben das Interesse geweckt, dieses Behandlungskonzept auch bei Patienten mit Hämoglobinopathien anzuwenden. In klinischen Studien wurde gezeigt, dass durch lentiviralen Transfer eines modifizierten β-Globingens in autologe hämatopoetische Stammzellen bei der Mehrzahl der β-Thalassämie-Patienten eine Transfusionsunabhängigkeit erreichbar ist und Sichelzellpatienten keine vasookklusiven Krisen mehr erleiden. Das Auftreten von zwei Leukämiefällen bei Sichelzellpatienten nach dieser Form der lentiviralen Gentherapie hat verdeutlicht, dass Weiterentwicklungen sinnvoll sind, um das Risiko von Integrationsereignissen und hämatopoetischen Neoplasien zu minimieren. Mit der neuartigen, im Jahr 2020 mit dem Nobelpreis ausgezeichneten Technologie der zielgerichteten CRISPR/Cas9-basierten Geneditierung hat ein solches Therapieverfahren kürzlich Einzug in die Klinik gehalten. In proof-of-concept-Studien konnte gezeigt werden, dass die CRISPR/Cas9-vermittelte Ausschaltung des erythrozytären Transkriptionsfaktors BCL11A in autologen hämatopoetischen Stammzellen die Expression fetalen Hämoglobins (HbF) reaktiviert und dass durch die stabile Produktion von HbF bedeutsame therapeutische Effekte bei Patienten mit Thalassämie und Sichelzellerkrankung erzielt werden.

ABSTRACT

The success of hematopoietic stem cell gene therapy in children with severe combined immunodeficiency has stimulated profound interest in implementing similar therapeutic strategies for patients with hemoglobinopathies. Clinical studies have shown that after lentiviral gene transfer of a modified β-globin gene into autologous hematopoietic stem cells the majority of β-thalassemia patients reach transfusion independency and patients with sickle cell disease do not experience further vasoocclusive events. The recent occurence of two leukemia cases in sickle cell patients after this form of treatment has shown that further development of gene therapy is needed to minimize the risk of unintentional genomic integration and subsequent hematologic malignancy. The nobel prize-winning approach of targeted CRISPR/Cas9-based genome editing has recently entered the clinic. Proof-of-concept studies have revealed that CRISPR/Cas9-mediated disruption of the erythroid-specific transcription factor BCL11A in autologous hematopoietic stem cells reactivates fetal hemoglobin (HbF) expression and that the resulting stable production of HbF provides meaningful therapeutic effects in patients with thalassemia and sickle cell disease.

Schlüsselwörter

Sichelzellerkrankung - β-Thalassämie - retroviraler Gentransfer - CRISPR/Cas9-Geneditierung - HbF-Induktion

Keywords

Sickle cell disease - β-Thalassemia - retroviral gene transfer - CRISR/Cas9 gene editing - HbF induction

Publication History

Received: 16 July 2021

Accepted: 26 July 2021

Article published online:
25 February 2022

• Literatur

• 1 Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med 2021; 384: 727-743 DOI: 10.1056/NEJMra2021838.
• 2 Gluckman E, Cappelli B, Bernaudin F. et al Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 2017; 129: 1548-1556 DOI: 10.1182/blood-2016-10-745711.
• 3 Bernardo ME, Piras E, Vacca A. et al Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012; 120: 473-476 DOI: 10.1182/blood-2012-04-423822.
• 4 Cavazzana-Calvo M, Payen E, Negre O. et al Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010; 467: 318-322 DOI: 10.1038/nature09328.
• 5 Thompson AA, Walters MC, Kwiatkowski J. et al Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med 2018; 378: 1479-1493 DOI: 10.1056/NEJMoa1705342.
• 6 Locatelli F, Kwiatkowski JL, Walters MCB. et al Betibeglogene autotemcel in patients with transfusion dependent β thalassemia: Updated results from HGB 207 (Northstar 2) and HGB 212 (Northstar 3). EHA 2021 Virtual Congress Abstract S266
• 7 Kwiatkowski JL, Thompson AA, Walters MCB. et al Resolution of serious vasoocclusive pain crises and reduction in patient reported pain intensity: Results from the ongoing Phase ½ HGB 206 group C study of LentiGlobin for sickle cell disease (bb1111) gene therapy. EHA 2021 Virtual Congress Abstract S261
• 8 Hsieh MM, Bonner M, Pierciey FJ. et al Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv 2020; 04: 2058-2063 DOI: 10.1182/bloodadvances.2019001330.
• 9 Brunson A, Keegan THM, Bang H. et al Increased risk of leukemia among sickle cell disease patients in California. Blood 2017; 130: 1597-1599 DOI: 10.1182/blood-2017-05-783233.
• 10 Jones RJ, DeBaun MR.. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither. Blood 2021 DOI: 10.1182/blood.2021011488. Online ahead of print
• 11 Jinek M, Chylinski K, Fonfara I. et al A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-821 DOI: 10.1126/science.1225829.
• 12 Ferrari G, Thrasher AJ, Aiuti A. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet 2021; 22: 216-234 DOI: 10.1038/s41576-020-00298-5.
• 13 Frangoul H, Altshuler D, Cappellini MD. et al CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med 2021; 384: 252-260 DOI: 10.1056/NEJMoa2031054.
• 14 Locatelli F, Ailinca-Luchian S, Bobruff YB. et al CTX001 for transfusion-dependent Β-Thalassemia: Safety and efficacy results from the ongoing CLIMB THAL-111 study of autologous CRISPR-Cas9-modified CD34 + hematopoietic stem and progenitor cells. EHA 2021 Virtual Congress. Abstract EP733
• 15 Grupp S, Bloberger N, Campbell CB. et al Safety and efficacy results from the ongoing CLIMB SCD-121 study of autologous CRISPR-Cas9-modified CD34 + hematopoietic stem and progenitor cells. EHA 2021 Virtual Congress. Abstract EP736
• 16 Lattanzi A, Camarena J, Lahiri P. et al Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med 2021; 13: eabf2444 DOI: 10.1126/scitranslmed.abf2444.
• 17 Newby GA, Yen JS, Woodard KJ. et al Base editing of hematopoietic stem cells rescues sickle cell disease in mice. Nature 2021; 595: 95-302 DOI: 10.1038/s41586-021-03609-w.
• 18 Li C, Wang H, Gil S. et al In Vivo HSC Gene Therapy for Hemoglobinopathies: A Proof of Concept Evaluation in Rhesus Macaques. Blood 2020; 136 (Suppl. 01) 46-47 https://doi.org/10.1182/blood-2020-141468
• 19 Pang WW, Czechowicz A, Logan AC. et al Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood 2019; 133: 2069-2078 DOI: 10.1182/blood-2018-06-858159.